Take ‘doomed’ cholesterol drug off the market, urges expert

A NEW cholesterol-lowering drug launched last year should be taken off the market because of its poor safety record, an expert said yesterday.

Writing in The Lancet medical journal, Dr Sidney Wolfe said the statin drug Crestor was "ultimately doomed".

The drug has been linked to a condition called rhabdomyolysis, a breakdown of muscle fibre which can cause kidney failure.

You have reached your article limit. Already a subscriber? Sign in

Unlimited access starts here.

Try from only €0.25 a day.

Cancel anytime

More in this section

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited